Healthcare | January 05, 2023
Viatris acquires Oyster Point Pharma and Famy Life Sciences
Acquisitions have the potential to add at least $1 billion in sales by 2028
Acquisitions have the potential to add at least $1 billion in sales by 2028
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
The Government of India is supporting the states in active case detection, surveillance, treatment, supply of diagnostic kits, medicines, sprays etc.
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
The company is one of the most profitable companies manufacturing speciality chemicals in India
The term of O&M is for 15 years with a lock in period of 5 years for the Company and 15 years for VHPL & Bharathi Education trust.
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Subscribe To Our Newsletter & Stay Updated
